| Literature DB >> 35402569 |
Seok Oh1, Ju Han Kim1,2, Kyung Hoon Cho1, Min Chul Kim1,2, Doo Sun Sim1,2, Young Joon Hong1,2, Youngkeun Ahn1,2, Myung Ho Jeong1,2.
Abstract
Objective: Although religion is expected to have a direct or indirect effect on various aspects of human life, information on the association between religion and acute myocardial infarction (AMI) is inadequate. Hence, in this study, we aimed to investigate the clinical effect of religion on clinical outcomes in patients with AMI.Entities:
Keywords: Republic of Korea; coronary artery disease; myocardial infarction; religion and medicine; treatment outcome
Year: 2022 PMID: 35402569 PMCID: PMC8984284 DOI: 10.3389/fcvm.2022.835969
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1Flowchart of study population. AMI, acute myocardial infarction; CNUH, Chonnam National University Hospital; and PCI, percutaneous coronary intervention.
FIGURE 2Religious distribution of the study population. (A) AMI patients who underwent successful PCI (n = 2,385). (B) Finally selected study patients (n = 2,348).
Baseline characteristics of the patients.
| Before propensity score weighting method | After PSM | After IPTW | |||||||
|
|
|
| |||||||
| Characteristics | Religious group | Non-religious group | Religious group | Non-religious group | Religious group | Non-religious group | |||
|
|
|
| |||||||
| ( | ( | ( | ( | ( | ( | ||||
| Male patients | 712 (62.7) | 973 (80.2) | <0.001 | 672 (73.8) | 674 (74.1) | 0.915 | 1,662 (71.8) | 1,662 (71.9) | 0.986 |
| Age ≥ 65 years | 668 (58.9) | 604 (49.8) | <0.001 | 480 (52.7) | 503 (55.3) | 0.279 | 1,248 (54.0) | 1,247 (53.9) | 0.985 |
| EMS utilization | 107 (8.8) | 95 (8.4) | 0.811 | 77 (8.5) | 82 (9.0) | 0.678 | 201 (8.7) | 199 (8.6) | 0.939 |
| TIT ≥ 12 h | 591 (52.1) | 595 (49.1) | 0.144 | 447 (49.1) | 471 (51.8) | 0.261 | 1,165 (50.4) | 1,166 (50.4) | 0.970 |
| S2DT ≥ 4 h | 184 (16.2) | 182 (15.0) | 0.420 | 138 (15.2) | 150 (16.5) | 0.441 | 358 (15.5) | 359 (15.5) | 0.971 |
| D2BT ≥ 90 min | 692 (61.0) | 687 (56.6) | 0.033 | 532 (58.5) | 552 (60.7) | 0.339 | 1,353 (58.5) | 1,351 (58.4) | 0.970 |
| Killip class III-IV | 136 (12.0) | 134 (11.0) | 0.478 | 97 (10.7) | 107 (11.8) | 0.457 | 263 (11.4) | 262 (11.3) | 0.983 |
| BMI ≥ 25 kg/m2 | 409 (36.3) | 421 (34.9) | 0.485 | 327 (35.9) | 334 (36.7) | 0.733 | 824 (35.6) | 825 (35.7) | 0.980 |
| Previous history | |||||||||
| Hypertension | 667 (58.8) | 595 (49.1) | <0.001 | 492 (54.1) | 516 (56.7) | 0.258 | 1,244 (53.8) | 1,245 (53.8) | 0.991 |
| Diabetes mellitus | 363 (32.0) | 366 (30.2) | 0.344 | 273 (30.0) | 294 (32.3) | 0.288 | 718 (31.0) | 717 (31.0) | 0.979 |
| Dyslipidemia | 93 (8.2) | 83 (6.8) | 0.214 | 68 (7.5) | 74 (8.1) | 0.600 | 175 (7.6) | 177 (7.7) | 0.938 |
| Old MI | 89 (7.8) | 105 (8.7) | 0.474 | 76 (8.3) | 68 (7.5) | 0.487 | 190 (8.2) | 190 (8.2) | 0.984 |
| Old heart failure | 15 (1.3) | 18 (1.5) | 0.738 | 13 (1.4) | 13 (1.4) | 1.000 | 30 (1.3) | 31 (1.3) | 0.953 |
| Old CVA | 74 (6.5) | 79 (6.5) | 0.994 | 63 (6.9) | 58 (6.4) | 0.638 | 152 (6.6) | 153 (6.6) | 0.976 |
| Smoking | 569 (50.1) | 813 (67.0) | <0.001 | 539 (59.2) | 529 (58.1) | 0.634 | 1,361 (58.9) | 1,362 (58.9) | 0.988 |
| Family history of CAD | 62 (5.5) | 61 (5.0) | 0.637 | 47 (5.2) | 54 (5.9) | 0.474 | 122 (5.3) | 120 (5.2) | 0.928 |
| LVEF < 40% | 120 (10.6) | 124 (10.3) | 0.800 | 80 (9.6) | 95 (10.4) | 0.532 | 240 (10.4) | 240 (10.4) | 0.997 |
| STEMI diagnosis | 451 (39.7) | 538 (44.4) | 0.024 | 385 (42.3) | 367 (40.3) | 0.392 | 977 (42.2) | 980 (42.4) | 0.944 |
| Discharge medications | |||||||||
| Aspirin | 1,134 (99.9) | 1,212 (99.9) | 0.962 | 909 (99.9) | 909 (99.9) | 1.000 | 2,311 (99.9) | 2,311 (99.9) | 1.000 |
| P2Y12 inhibitors | 1,134 (99.9) | 1,212 (99.9) | 0.962 | 909 (99.9) | 910 (100.0) | 1.000 | 2,311 (99.9) | 2,311 (99.9) | 1.000 |
| Beta-blockers | 981 (86.4) | 1,041 (85.8) | 0.669 | 789 (86.7) | 785 (86.3) | 0.784 | 1,995 (86.3) | 1,993 (86.2) | 0.971 |
| ACE inhibitor or ARB | 992 (87.4) | 1,057 (87.1) | 0.849 | 806 (88.6) | 795 (87.4) | 0.428 | 2,023 (87.5) | 2,022 (87.4) | 0.983 |
| Statins | 1,062 (93.6) | 1,144 (94.3) | 0.450 | 855 (94.0) | 849 (93.3) | 0.565 | 2,175 (94.0) | 2,176 (94.1) | 0.942 |
Values are presented as number (percentage) for categorical values and means ± standard deviation for continuous variables. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CrCl, creatinine clearance; CVA, cerebrovascular accidents; EMS, emergency medical service; IPTW, inverse probability of treatment weighting; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PSM, propensity score matching.
Coronary angiographic and procedural characteristics of the study population.
| Before propensity score weighting | After PSM | After IPTW | |||||||
|
|
|
| |||||||
| Characteristics | Religious group | Non-religious group | Religious group | Non-religious group | Religious group | Non-religious group | |||
|
|
|
| |||||||
| ( | ( | ( | ( | ( | ( | ||||
| Use of transfemoral approach | 602 (53.0) | 669 (55.2) | 0.305 | 492 (54.1) | 471 (51.8) | 0.324 | 1,243 (53.7) | 1,244 (53.8) | 0.968 |
| Use of GPIIb/IIIa inhibitor | 159 (14.0) | 169 (13.9) | 0.957 | 123 (13.5) | 141 (15.5) | 0.231 | 326 (14.1) | 323 (14.0) | 0.938 |
| Use of thrombus aspiration | 176 (15.5) | 219 (18.1) | 0.099 | 147 (16.1) | 161 (17.7) | 0.381 | 395 (17.1) | 391 (16.9) | 0.925 |
| Use of image-guided PCI | 51 (4.5) | 76 (6.3) | 0.058 | 47 (5.2) | 40 (4.4) | 0.442 | 129 (5.6) | 126 (5.4) | 0.892 |
| LMCA or LAD as an IRA | 556 (49.0) | 590 (48.6) | 0.866 | 446 (49.0) | 440 (48.3) | 0.778 | 1,139 (49.2) | 1,141 (49.3) | 0.956 |
| Use of thrombolysis | 1 (0.1) | 3 (0.2) | 0.626 | 1 (0.1) | 1 (0.1) | 1.000 | 3 (0.1) | 4 (0.2) | 0.742 |
| Preprocedural TIMI flow grade 0-I | 558 (49.2) | 636 (52.4) | 0.113 | 471 (51.8) | 452 (49.7) | 0.373 | 1,185 (51.2) | 1,189 (51.4) | 0.941 |
Values are presented as number (percentage) for categorical values and means ± standard deviation for continuous variables. GPIIb/IIIa, glycoprotein IIb/IIIa; IPTW, inverse probability of treatment weighting; LAD, left anterior descending coronary artery; LMCA, left main coronary artery; PCI, percutaneous coronary intervention; PSM, propensity score matching; TIMI, Thrombolysis in Myocardial Infarction.
One-year clinical outcomes in propensity score matched post-discharge survivors.
| Outcomes | Religious group | Non-religious group | Unadjusted analysis | PSM-adjusted analysis | IPTW-adjusted analysis | |||
|
|
|
|
|
| ||||
| ( | ( | HR (95% CI) (a) | HR (95% CI) (b) | HR (95% CI) (b) | ||||
| MACCE (c) | 176 (15.6) | 184 (15.3) | 0.975 (0.793–1.199) | 0.811 | 1.113 (0.878–1.410) | 0.377 | 1.077 (0.869–1.336) | 0.497 |
| NACE | 138 (12.2) | 144 (12.0) | 0.968 (0.766–1.222) | 0.783 | 1.134 (0.870–1.477) | 0.352 | 1.067 (0.838–1.358) | 0.598 |
| All-cause death | 76 (6.7) | 89 (7.4) | 1.093 (0.805–1.485) | 0.568 | 1.217 (0.854–1.733) | 0.278 | 1.237 (0.894–1.711) | 0.199 |
| Cardiac death | 48 (4.3) | 54 (4.5) | 1.049 (0.711–1.548) | 0.809 | 1.249 (0.805–1.937) | 0.321 | 1.214 (0.807–1.826) | 0.353 |
| Non-cardiac death | 28 (2.5) | 35 (2.9) | 1.169 (0.711–1.922) | 0.538 | 1.158 (0.636–2.109) | 0.631 | 1.280 (0.750–2.187) | 0.366 |
| NFMI | 36 (3.2) | 42 (3.5) | 1.086 (0.695–1.695) | 0.718 | 1.418 (0.840–2.393) | 0.191 | 1.291 (0.815–2.045) | 0.276 |
| Any revascularization | 56 (5.0) | 63 (5.2) | 1.028 (0.717–1.474) | 0.880 | 1.320 (0.884–1.972) | 0.175 | 1.110 (0.768–1.604) | 0.578 |
| Rehospitalization due to angina | 42 (3.7) | 34 (2.8) | 0.757 (0.482–1.190) | 0.228 | 0.750 (0.442–1.274) | 0.288 | 0.843 (0.529–1.345) | 0.474 |
| CVA | 17 (1.5) | 17 (1.4) | 0.926 (0.473–1.814) | 0.822 | 1.109 (0.471–2.610) | 0.814 | 1.153 (0.572–2.322) | 0.690 |
| Stent thrombosis | 6 (0.5) | 10 (0.8) | 1.429 (0.516–3.957) | 0.492 | 1.971 (0.598–6.495) | 0.265 | 1.517 (0.548–4.204) | 0.423 |
Values are presented as percentage (number) for categorical values.
BMI, body mass index; CI, confidence interval; CVA, cerebrovascular accident; D2BT, door-to-balloon time; HR, hazard ratio; IPTW, inverse probability of treatment weighting; IRA, infarct-related artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; NACE, net adverse clinical events; NFMI, non-fatal myocardial infarction; PCI, percutaneous coronary intervention; PSM, propensity score matching; RCA, right coronary artery; S2DT, symptom-to-door time; TIMI, Thrombolysis In Myocardial Infarction; TIT, total ischemic time.
(a) HR corresponds to the non-religious group compared with the religious group. (b) The adjusted Cox hazards regression analysis included various clinical variables, including sex, age, utilization of emergency medical service, S2DT, D2BT, TIT, hospital visit timing (off-hour vs. on-hour admission), Killip classification, BMI, previous medical history (hypertension, diabetes mellitus, dyslipidemia, old myocardial infarction, prior heart failure, old CVA), smoking history, family coronary artery disease history, prescribed medications (aspirin, P2Y12 inhibitors, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins), vascular approach, use of glycoprotein IIb/IIIa inhibitors, use of thrombus aspiration, use of image-guided PCI, IRA (LMCA or LAD vs. LCX or RCA), preprocedural TIMI flow grade, use of thrombolysis, and LVEF. (c) MACCE is defined as a composite of all-cause mortality, non-fatal myocardial infarction, any revascularization, cerebrovascular accident, and stent thrombosis.
FIGURE 3Incidences of primary and secondary clinical outcomes in all patients after a 1-year follow-up (before PSM- or IPTW-adjusted analysis). The figure shows the Kaplan–Meier curves for cumulative event rates according to the presence or absence of religious faith. IPTW, inverse probability of treatment weighting; PSM, propensity score matching.
FIGURE 5Incidences of primary and secondary clinical outcomes in all patients after a 1-year follow-up (after IPTW-adjusted analysis). The figure shows the Kaplan–Meier curves for the cumulative event rates according to their religious faith. IPTW, inverse probability of treatment weighting.
FIGURE 6Incidences of primary and secondary clinical outcomes for all patients in a landmark analysis between 90 days and 1 year (before PSM- or IPTW-adjusted analysis). The figure shows the Kaplan–Meier curves for the cumulative event rates according to their religious faith. IPTW, inverse probability of treatment weighting; PSM, propensity score matching.
FIGURE 8Incidences of primary and secondary clinical outcomes for all patients in a landmark analysis between 90 days and 1 year (after IPTW-adjusted analysis). The figure shows the Kaplan–Meier curves for the cumulative event rates according to their religious faith. IPTW, inverse probability of treatment weighting.